The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice

Debomoy K. Lahiri, De Mao Chen, Bryan Maloney, Harold W. Holloway, Qian Sheng Yu, Tada Utsuki, Tony Giordano, Kumar Sambamurti, Nigel H. Greig

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Major characteristics of Alzheimer's disease (AD) are synaptic loss, cholinergic dysfunction, and abnormal protein depositions in the brain. The amyloid β-peptide (Aβ), a proteolytic fragment of amyloid β precursor protein (APP), aggregates to form neuritic plaques and has a causative role in AD. A present focus of AD research is to develop safe Aβ-lowering drugs. A selective acetylcholinesterase inhibitor, phenserine, in current human trials lowers both APP and Aβ. Phenserine is dose-limited in animals by its cholinergic actions; its cholinergically inactive enantiomer, posiphen (+)-[phenserine], was assessed. In cultured human neuroblastoma cells, posiphen, like phenserine, dose- and time-dependently lowered APP and Aβ levels by reducing the APP synthesis rate. This action translated to an in vivo system. Posiphen administration to mice (7.5-75 mg/kg daily, 21 consecutive days) significantly decreased levels of total APP (tissue mass-adjusted) in a dose-dependent manner. Aβ40 and Aβ42 levels were significantly lowered by posiphen (≥15 mg/kg) compared with controls. The activities of α-, β-, and γ-secretases were assessed in the same brain samples, and β-secretase activity was significantly reduced. Posiphen, like phenserine, can lower Aβ via multiple mechanisms and represents an interesting drug candidate for AD treatment.

Original languageEnglish (US)
Pages (from-to)386-396
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume320
Issue number1
DOIs
StatePublished - Jan 5 2007

Fingerprint

Amyloid
Alzheimer Disease
Cell Culture Techniques
Peptides
Serum Amyloid A Protein
Pharmaceutical Preparations
Amyloid beta-Protein Precursor
Amyloid Precursor Protein Secretases
Cholinergic Agents
phenserine
Cholinesterase Inhibitors
Amyloid Plaques
Brain
Neuroblastoma
Research

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice. / Lahiri, Debomoy K.; Chen, De Mao; Maloney, Bryan; Holloway, Harold W.; Yu, Qian Sheng; Utsuki, Tada; Giordano, Tony; Sambamurti, Kumar; Greig, Nigel H.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 320, No. 1, 05.01.2007, p. 386-396.

Research output: Contribution to journalArticle

Lahiri, Debomoy K. ; Chen, De Mao ; Maloney, Bryan ; Holloway, Harold W. ; Yu, Qian Sheng ; Utsuki, Tada ; Giordano, Tony ; Sambamurti, Kumar ; Greig, Nigel H. / The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice. In: Journal of Pharmacology and Experimental Therapeutics. 2007 ; Vol. 320, No. 1. pp. 386-396.
@article{3d080a4af2774679afbae4cbbf15e9b8,
title = "The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice",
abstract = "Major characteristics of Alzheimer's disease (AD) are synaptic loss, cholinergic dysfunction, and abnormal protein depositions in the brain. The amyloid β-peptide (Aβ), a proteolytic fragment of amyloid β precursor protein (APP), aggregates to form neuritic plaques and has a causative role in AD. A present focus of AD research is to develop safe Aβ-lowering drugs. A selective acetylcholinesterase inhibitor, phenserine, in current human trials lowers both APP and Aβ. Phenserine is dose-limited in animals by its cholinergic actions; its cholinergically inactive enantiomer, posiphen (+)-[phenserine], was assessed. In cultured human neuroblastoma cells, posiphen, like phenserine, dose- and time-dependently lowered APP and Aβ levels by reducing the APP synthesis rate. This action translated to an in vivo system. Posiphen administration to mice (7.5-75 mg/kg daily, 21 consecutive days) significantly decreased levels of total APP (tissue mass-adjusted) in a dose-dependent manner. Aβ40 and Aβ42 levels were significantly lowered by posiphen (≥15 mg/kg) compared with controls. The activities of α-, β-, and γ-secretases were assessed in the same brain samples, and β-secretase activity was significantly reduced. Posiphen, like phenserine, can lower Aβ via multiple mechanisms and represents an interesting drug candidate for AD treatment.",
author = "Lahiri, {Debomoy K.} and Chen, {De Mao} and Bryan Maloney and Holloway, {Harold W.} and Yu, {Qian Sheng} and Tada Utsuki and Tony Giordano and Kumar Sambamurti and Greig, {Nigel H.}",
year = "2007",
month = "1",
day = "5",
doi = "10.1124/jpet.106.112102",
language = "English (US)",
volume = "320",
pages = "386--396",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice

AU - Lahiri, Debomoy K.

AU - Chen, De Mao

AU - Maloney, Bryan

AU - Holloway, Harold W.

AU - Yu, Qian Sheng

AU - Utsuki, Tada

AU - Giordano, Tony

AU - Sambamurti, Kumar

AU - Greig, Nigel H.

PY - 2007/1/5

Y1 - 2007/1/5

N2 - Major characteristics of Alzheimer's disease (AD) are synaptic loss, cholinergic dysfunction, and abnormal protein depositions in the brain. The amyloid β-peptide (Aβ), a proteolytic fragment of amyloid β precursor protein (APP), aggregates to form neuritic plaques and has a causative role in AD. A present focus of AD research is to develop safe Aβ-lowering drugs. A selective acetylcholinesterase inhibitor, phenserine, in current human trials lowers both APP and Aβ. Phenserine is dose-limited in animals by its cholinergic actions; its cholinergically inactive enantiomer, posiphen (+)-[phenserine], was assessed. In cultured human neuroblastoma cells, posiphen, like phenserine, dose- and time-dependently lowered APP and Aβ levels by reducing the APP synthesis rate. This action translated to an in vivo system. Posiphen administration to mice (7.5-75 mg/kg daily, 21 consecutive days) significantly decreased levels of total APP (tissue mass-adjusted) in a dose-dependent manner. Aβ40 and Aβ42 levels were significantly lowered by posiphen (≥15 mg/kg) compared with controls. The activities of α-, β-, and γ-secretases were assessed in the same brain samples, and β-secretase activity was significantly reduced. Posiphen, like phenserine, can lower Aβ via multiple mechanisms and represents an interesting drug candidate for AD treatment.

AB - Major characteristics of Alzheimer's disease (AD) are synaptic loss, cholinergic dysfunction, and abnormal protein depositions in the brain. The amyloid β-peptide (Aβ), a proteolytic fragment of amyloid β precursor protein (APP), aggregates to form neuritic plaques and has a causative role in AD. A present focus of AD research is to develop safe Aβ-lowering drugs. A selective acetylcholinesterase inhibitor, phenserine, in current human trials lowers both APP and Aβ. Phenserine is dose-limited in animals by its cholinergic actions; its cholinergically inactive enantiomer, posiphen (+)-[phenserine], was assessed. In cultured human neuroblastoma cells, posiphen, like phenserine, dose- and time-dependently lowered APP and Aβ levels by reducing the APP synthesis rate. This action translated to an in vivo system. Posiphen administration to mice (7.5-75 mg/kg daily, 21 consecutive days) significantly decreased levels of total APP (tissue mass-adjusted) in a dose-dependent manner. Aβ40 and Aβ42 levels were significantly lowered by posiphen (≥15 mg/kg) compared with controls. The activities of α-, β-, and γ-secretases were assessed in the same brain samples, and β-secretase activity was significantly reduced. Posiphen, like phenserine, can lower Aβ via multiple mechanisms and represents an interesting drug candidate for AD treatment.

UR - http://www.scopus.com/inward/record.url?scp=33845905829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845905829&partnerID=8YFLogxK

U2 - 10.1124/jpet.106.112102

DO - 10.1124/jpet.106.112102

M3 - Article

C2 - 17003227

AN - SCOPUS:33845905829

VL - 320

SP - 386

EP - 396

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -